Abstract 2791
Background
ULTIMATE, a phase III trial, showed a significant superiority in terms of progression free survival (PFS) and less toxicity of the combination paclitaxel-bevacizumab versus docetaxel as second or third-line treatment. With the growing role of immunotherapy as first-line setting for advanced non-small cell lung cancer (NSCLC), there is a need to redefine strategies to failure. The use of the paclitaxel-bevacizumab combination could be an option.
Methods
This retrospective study identified patients treated with paclitaxel and bevacizumab according to the ULTIMATE study in 3 centers in France. Main objectives were to describe safety and efficacy of this combination in metastatic non-squamous NSCLC as second-line therapy or beyond, with a particular interest for the sub-group of patients treated just after immune checkpoint inhibitors.
Results
From 1st September 2010 to 1st avril 2018, 76 patients started the paclitaxel-bevacizumab combination : 42 (55%) male, 18 (24%) and 36 (47%) treated in second and third-line respectively, and 22 (29%) in fourth-line or more. Objective response rate (ORR) was 37% (28/76) and disease control rate 74 % (56/76). Median PFS and OS were 5,7 [95%CI: 4,1-6,9] months and 11,2 [95%CI: 8-not reached] months respectively. For patients treated in second and third-line, ORR was respectively 39% and 42%, PFS 4 months [95%CI: 2,5-7,7] and 6 months [95%CI: 4-7], OS 9,4 months [95%CI: 2,7-not reached] and was not reached in third-line at 12 months. Grade 3–4 adverse events included asthenia 5% (4/76), neurotoxicity 3% (2/76), bleeding events 4% (3/76), and hematological toxicity 1% (1/76). Interestingly, in the subgroup of patients treated with immunotherapy just before paclitaxel-bevacizumab (33/76), ORR was 42% (14/33), median PFS was 6,2 [95% CI: 4,6-7,7] months, and median overall survival was not reached at 12 months.
Conclusions
This results exhibited an acceptable toxicity profile and an encouraging efficacy as second-line treatment or beyond for non-squamous NSCLC patients. For patient treated just after immunotherapy the results are very promising.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Chantal Decroisette CH Annecy Genevois France.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract